These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35236742)

  • 1. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
    Glez-Vaz J; Azpilikueta A; Olivera I; Cirella A; Teijeira A; Ochoa MC; Alvarez M; Eguren-Santamaria I; Luri-Rey C; Rodriguez-Ruiz ME; Nie X; Chen L; Guedan S; Sanamed MF; Perez Gracia JL; Melero I
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
    Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
    ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.
    Labiano S; Palazón A; Bolaños E; Azpilikueta A; Sánchez-Paulete AR; Morales-Kastresana A; Quetglas JI; Perez-Gracia JL; Gúrpide A; Rodriguez-Ruiz M; Aznar MA; Jure-Kunkel M; Berraondo P; Melero I
    Oncoimmunology; 2016; 5(1):e1062967. PubMed ID: 26942078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.
    Yi L; Jin X; Wang J; Yan Z; Cheng X; Wen T; Yang B; Wang X; Che N; Liu Z; Zhang H
    Front Immunol; 2022; 13():771809. PubMed ID: 35197968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.
    Melero I; Sanmamed MF; Glez-Vaz J; Luri-Rey C; Wang J; Chen L
    Cancer Discov; 2023 Mar; 13(3):552-569. PubMed ID: 36576322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients.
    Räth U; Mester P; Schwarz H; Schmid S; Müller M; Buechler C; Pavel V
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
    Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
    Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice.
    Kachapati K; Bednar KJ; Adams DE; Wu Y; Mittler RS; Jordan MB; Hinerman JM; Herr AB; Ridgway WM
    J Autoimmun; 2013 Dec; 47():94-103. PubMed ID: 24145149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
    Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
    Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BT7480, a novel fully synthetic
    Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
    Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
    Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of soluble murine CD137 and its association with systemic lupus.
    Shao Z; Sun F; Koh DR; Schwarz H
    Mol Immunol; 2008 Sep; 45(15):3990-9. PubMed ID: 18640726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity.
    Ceccarelli F; Natalucci F; Di Filippo A; Olivieri G; Napoletano C; Rughetti A; Nuti M; Zizzari IG; Conti F
    J Immunol Res; 2023; 2023():2344239. PubMed ID: 37114204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
    Zizzari IG; Di Filippo A; Botticelli A; Strigari L; Pernazza A; Rullo E; Pignataro MG; Ugolini A; Scirocchi F; Di Pietro FR; Rossi E; Gelibter A; Schinzari G; D'Amati G; Rughetti A; Marchetti P; Nuti M; Napoletano C
    Clin Cancer Res; 2022 Mar; 28(5):1027-1037. PubMed ID: 34980602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
    Liu G; Luo P
    Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes.
    Michel J; Schwarz H
    Cytokine; 2000 Jun; 12(6):742-6. PubMed ID: 10843756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced levels of soluble and membrane-bound CD137 levels in patients with acute coronary syndromes.
    Dongming L; Zuxun L; Liangjie X; Biao W; Ping Y
    Clin Chim Acta; 2010 Mar; 411(5-6):406-10. PubMed ID: 20026323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.